{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T18:02:11Z","timestamp":1770832931915,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","celltherapyjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jcyt.2024.02.013","type":"journal-article","created":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T16:49:38Z","timestamp":1708793378000},"page":"714-718","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Insights from CTTACC: immune system reset by cellular therapies for chronic illness after trauma, infection, and burn"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3822-6019","authenticated-orcid":false,"given":"Kenneth","family":"Bertram","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Cox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hasan","family":"Alam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0467-7073","authenticated-orcid":false,"given":"Clifford","family":"Lowell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Cuschieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biju","family":"Parekkadan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shibani","family":"Pati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2024.02.013_bib0001","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1056\/NEJMp048317","article-title":"Casualties of war\u2014military care for the wounded from Iraq and Afghanistan","volume":"351","author":"Gawande","year":"2004","journal-title":"NEJM"},{"key":"10.1016\/j.jcyt.2024.02.013_bib0002","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1001\/jamasurg.2019.0151","article-title":"Use of combat casualty care data to assess the US military trauma system during the Afghanistan and Iraq conflicts, 2001\u20132017","volume":"154","author":"Howard","year":"2019","journal-title":"JAMA Surg"},{"key":"10.1016\/j.jcyt.2024.02.013_bib0003","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/jama.2015.12","article-title":"Transfusion of plasma platelets and red blood cells in a 1:1:1 versus 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial","volume":"313","author":"Holcomb","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jcyt.2024.02.013_bib0004","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.surg.2018.04.011","article-title":"Persistent inflammation, immunosuppression, and catabolism and the development of chronic critical illness after surgery","volume":"164","author":"Efron","year":"2018","journal-title":"Surgery"},{"key":"10.1016\/j.jcyt.2024.02.013_bib0005","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3389\/fimmu.2018.01511","article-title":"Chronic clinical critical illness and the persistent inflammation, immunosuppression, and catabolism syndrome","volume":"2","author":"Hawkins","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2024.02.013_bib0006","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/s41467-022-28338-0","article-title":"Mesenchymal stem cells transfer mitochondria to allogeneic Tregs in an HLA-dependent manner improving their immunosuppressive activity","volume":"13","author":"Piekarska","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcyt.2024.02.013_bib0007","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1089\/neu.2014.3535","article-title":"Fresh frozen plasma resuscitation provides neuroprotection compared to normal saline in a large animal model of traumatic brain injury and polytrauma","volume":"32","author":"Imam","year":"2015","journal-title":"J Neurotrauma"},{"key":"10.1016\/j.jcyt.2024.02.013_bib0008","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jamcollsurg.2015.01.057","article-title":"Early resuscitation with fresh frozen plasma for traumatic brain injury combined with hemorrhagic shock improves neurologic recovery","volume":"220","author":"Halaweish","year":"2015","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.jcyt.2024.02.013_bib0009","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jamcollsurg.2016.09.015","article-title":"Fresh frozen plasma modulates brain gene expression in a swine model of traumatic brain injury and shock: a network analysis","volume":"224","author":"Sillesen","year":"2017","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.jcyt.2024.02.013_bib0010","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1097\/TA.0b013e3182782641","article-title":"Pharmacologic resuscitation for hemorrhagic shock combined with traumatic brain injury","volume":"73","author":"Jin","year":"2012","journal-title":"J Trauma Acute Care Surg"},{"key":"10.1016\/j.jcyt.2024.02.013_bib0011","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1523\/JNEUROSCI.2469-20.2020","article-title":"Traumatic brain injury causes chronic cortical inflammation and neuronal dysfunction mediated by microglia","volume":"41","author":"Witcher","year":"2021","journal-title":"J Neurosci"},{"key":"10.1016\/j.jcyt.2024.02.013_bib0012","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/ana.22455","article-title":"Inflammation after trauma: microglial activation after traumatic brain injury","volume":"70","author":"Ramlackhansingh","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jcyt.2024.02.013_bib0013","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1146\/annurev-immunol-101921-050835","article-title":"Interfering with interferons: a critical mechanism for critical COVID-19 pneumonia","volume":"41","author":"Su","year":"2023","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jcyt.2024.02.013_bib0014","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13073-023-01173-8","article-title":"Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19","volume":"15","author":"Matuozzo","year":"2023","journal-title":"Genome Med"},{"key":"10.1016\/j.jcyt.2024.02.013_bib0015","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41590-022-01367-z","article-title":"Adaptive immune responses to SARS-CoV-2 persist in the pharyngeal lymphoid tissue of children","volume":"24","author":"Xu","year":"2023","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jcyt.2024.02.013_bib0016","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3390\/v15020400","article-title":"Persistent SARS-CoV-2 infection, EBV, HVV-6 and other factors may contribute to inflammation and autoimmunity in long COVID","volume":"15","author":"Vojdani","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.jcyt.2024.02.013_bib0017","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1084\/jem.20111354","article-title":"Inflammation and host response to injury large-scale collaborative research program. A genomic storm in critically injured humans","volume":"208","author":"Xiao","year":"2011","journal-title":"J Exp Med"},{"key":"10.1016\/j.jcyt.2024.02.013_bib0018","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/TA.0000000000003029","article-title":"Distinct immunologic endotypes are associated with clinical trajectory after severe blunt trauma and hemorrhagic shock","volume":"90","author":"Brakenridge","year":"2021","journal-title":"J Trauma Acute Care Surg"},{"key":"10.1016\/j.jcyt.2024.02.013_bib0019","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/TA.0000000000002952","article-title":"Persistent metabolomic alterations characterize chronic critical illness after severe trauma","volume":"90","author":"Horn","year":"2021","journal-title":"J Trauma Acute Care Surg"},{"key":"10.1016\/j.jcyt.2024.02.013_bib0020","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41582-022-00736-4","article-title":"Cell based therapies for neurological disorders\u2014the bioreactor hypothesis","volume":"19","author":"Savitz","year":"2023","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.jcyt.2024.02.013_bib0021","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.stem.2011.06.008","article-title":"The MSC: an injury drugstore","volume":"9","author":"Caplan","year":"2011","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jcyt.2024.02.013_bib0022","doi-asserted-by":"crossref","first-page":"10142","DOI":"10.1038\/s41598-020-67039-w","article-title":"Mesenchymal stromal cell bioreactor for ex vivo reprogramming of human immune cells","volume":"10","author":"Allen","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcyt.2024.02.013_bib0023","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/sctm.20-0454","article-title":"Mesenchymal stromal cell delivery via an ex vivo bioreactor preclinical test system attenuates clot formation for intravascular application","volume":"10","author":"O'Rourke","year":"2021","journal-title":"Stem Cells Transl Med"},{"key":"10.1016\/j.jcyt.2024.02.013_bib0024","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/sctm.21-0043","article-title":"Pharmacological effects of ex vivo mesenchymal stem cell immunotherapy in patients with acute kidney injury and underlying systemic inflammation","volume":"10","author":"Swaminathan","year":"2021","journal-title":"Stem Cells Transl Med"},{"key":"10.1016\/j.jcyt.2024.02.013_bib0025","unstructured":"US FDA. Guidance for industry on potency tests for cellular and gene therapy products (2011). Available at:https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/potency-tests-cellular-and-gene-therapy-products"},{"key":"10.1016\/j.jcyt.2024.02.013_bib0026","first-page":"1","article-title":"Commonalities between COVID-19 and radiation injury","volume":"195","author":"Rios","year":"2021","journal-title":"Radiat Res"},{"key":"10.1016\/j.jcyt.2024.02.013_bib0027","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.addr.2017.10.003","article-title":"The application of mesenchymal stem cells to treat thermal and radiation burns","volume":"123","author":"Rodgers","year":"2018","journal-title":"Adv Drug Deliv Rev"},{"issue":"Suppl 1","key":"10.1016\/j.jcyt.2024.02.013_bib0028","doi-asserted-by":"crossref","DOI":"10.1136\/tsaco-2023-001123","article-title":"Blood product use for radiological\/nuclear trauma: product development and US regulatory considerations","volume":"9","author":"Silverman","year":"2024","journal-title":"Trauma Surg Acute Care Open"},{"key":"10.1016\/j.jcyt.2024.02.013_bib0029","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.3389\/fimmu.2018.01931","article-title":"Sex hormones determine immune response","volume":"9","author":"Taneja","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2024.02.013_bib0030","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/j.injury.2007.09.027","article-title":"Trauma and immune response\u2014effect of gender differences","volume":"38","author":"Choundry","year":"2007","journal-title":"Injury"},{"key":"10.1016\/j.jcyt.2024.02.013_bib0031","unstructured":"National Institutes of Health. NIH policy and guidelines on the inclusion of women and minorities as subjects in clinical research (2001). Available at: https:\/\/grants.nih.gov\/policy\/inclusion\/women-and-minorities\/guidelines.htm"},{"key":"10.1016\/j.jcyt.2024.02.013_bib0032","doi-asserted-by":"crossref","first-page":"e12712","DOI":"10.1111\/cpr.12712","article-title":"Immune modulation by mesenchymal stem cells","volume":"53","author":"Jiang","year":"2020","journal-title":"Cell Proliferation"},{"key":"10.1016\/j.jcyt.2024.02.013_bib0033","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.stem.2018.05.004","article-title":"Mesenchymal stromal cells: clinical challenges and therapeutic opportunities","volume":"22","author":"Galipeau","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jcyt.2024.02.013_bib0034","unstructured":"US FDA. Manufacturing changes and comparability for human cellular and gene therapy products (2023). Available at:https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/manufacturing-changes-and-comparability-human-cellular-and-gene-therapy-products."}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324924000598?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324924000598?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T13:57:49Z","timestamp":1720879069000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324924000598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1465324924000598"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2024.02.013","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Insights from CTTACC: immune system reset by cellular therapies for chronic illness after trauma, infection, and burn","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2024.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}